Eleftherios Zografos
Research Subjects
Eleftherios Zografos has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Adriano Gravina
Clinical Trial Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples
6 shared publications - Ana Oaknin
Vall d’Hebron Institute of Oncology (VHIO) 7 Medical Oncology Service, Vall d’Hebron Barcelona Hospital Campus, Instituto de Investigación Sanitaria Hospital Universitari Vall d’Hebron (IIS IR-HUVH) Barcelona, Spain
6 shared publications - Anna V. Tinker
Division of Gynecologic Oncology, Vancouver Coastal Health; Department of Obstetrics and Gynecology, Faculty of Medicine, University of British Columbia, Vancouver, BC V6H 3N1, Canada
6 shared publications - Bhavana Pothuri
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, New York University Grossman School of Medicine, United States
6 shared publications - Cara Mathews
Program in Women's Oncology, Women & Infants Hospital, Legorreta Cancer Center at Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI, USA
6 shared publications - David M. O'MAlley
The Ohio State University, James Cancer Center, Columbus, OH
6 shared publications
Latest Publications
- Open Access
- 18 February 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (3) , e70196
Model‐Based Meta‐Analysis of Objective Response Rate and Survival Endpoints to Compare PD ‐1 and PD ‐ L1 Treatment Outcomes in Non‐Small Cell Lung Cancer
Programmed cell death (PD) protein (ligand [L])‐1 inhibitors are established treatments for metastatic non‐small cell lung cancer (mNSCLC). In oncology, progression‐free survival (PFS) and objective response rate (ORR) are often used as surrogates for overall survival (OS) to inform clinical development; however, there remains uncertainty in the concordance between these endpoints. This study evaluated the impact of a broad set of PD‐(L)1 inhibitors on efficacy, explored the relationship between ORR and survival endpoints, and compared PD‐1 and PD‐L1 treatments for mNSCLC. A dataset of 114 studies was used to conduct a sequential two‐stage model‐based meta‐analysis (MBMA). Firstly, an MBMA with mixed‐effects logistic regression was applied to evaluate treatment‐specific and clinical covariate effects on ORR. Secondly, MBMAs for OS and PFS were conducted with a mixed‐effects semi‐parametric proportional hazard approach using digitized Kaplan–Meier curves, with the treatment type, covariates, and ORR as inputs. ORR was demonstrated to be a significant predictor of OS and PFS. Simulations of head‐to‐head comparisons of treatment types were conducted using these models. Trends in predicted outcomes numerically favored PD‐1 over PD‐L1 treatments, but differences were not statistically significant. These findings support evidence‐based decision‐making for late‐stage trial designs using ORR data from earlier phase trials, enabling benchmarking of emerging data by adjusting for explained and unexplained sources of variability in existing and emerging data.
- 18 February 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (3) , e70196
Open AccessModel‐Based Meta‐Analysis of Objective Response Rate and Survival Endpoints to Compare PD ‐1 and PD ‐ L1 Treatment Outcomes in Non‐Small Cell Lung Cancer
Programmed cell death (PD) protein (ligand [L])‐1 inhibitors are established treatments for metastatic non‐small cell lung cancer (mNSCLC). In oncology, progression‐free survival (PFS) and objective response rate (ORR) are often used as surrogates for overall survival (OS) to inform clinical development; however, there remains uncertainty in the concordance between these endpoints. This study evaluated the impact of a broad set of PD‐(L)1 inhibitors on efficacy, explored the relationship between ORR and survival endpoints, and compared PD‐1 and PD‐L1 treatments for mNSCLC. A dataset of 114 studies was used to conduct a sequential two‐stage model‐based meta‐analysis (MBMA). Firstly, an MBMA with mixed‐effects logistic regression was applied to evaluate treatment‐specific and clinical covariate effects on ORR. Secondly, MBMAs for OS and PFS were conducted with a mixed‐effects semi‐parametric proportional hazard approach using digitized Kaplan–Meier curves, with the treatment type, covariates, and ORR as inputs. ORR was demonstrated to be a significant predictor of OS and PFS. Simulations of head‐to‐head comparisons of treatment types were conducted using these models. Trends in predicted outcomes numerically favored PD‐1 over PD‐L1 treatments, but differences were not statistically significant. These findings support evidence‐based decision‐making for late‐stage trial designs using ORR data from earlier phase trials, enabling benchmarking of emerging data by adjusting for explained and unexplained sources of variability in existing and emerging data.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
This includes supplementary tables and figures
- Top Cited PapersOpen Access
- 26 June 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (22) , 4564-4574
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Purpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. Patients and Methods: A total of 153 patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and 161 patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) EC were enrolled and dosed. Patients received 500 mg dostarlimab every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression. Primary endpoints were objective response rate (ORR) and duration of response (DOR). Results: A total of 143 patients with dMMR/MSI-H EC and 156 patients with MMRp/MSS EC were evaluated for efficacy. ORR was 45.5% (n = 65) and 15.4% (n = 24) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. Median DOR for dMMR/MSI-H EC was not met (median follow-up, 27.6 months); median DOR for MMRp/MSS EC was 19.4 months. The ORRs by combined positive score (CPS) ≥1 status were 54.9% and 21.7% for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORRs by high tumor mutational burden (≥10 mutations/Mb) were 47.8% (43/90) and 45.5% (5/11) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORR in TP53mut or POLεmut molecular subgroups was 18.1% (17/94) and 40.0% (2/5), respectively. The safety profile of dostarlimab was consistent with previous reports. Conclusions: Dostarlimab demonstrated durable antitumor activity and safety in patients with dMMR/MSI-H EC. Biomarkers associated with EC may identify patients likely to respond to dostarlimab. See related commentary by Jangra and Dhani, p. 4521
- 26 June 2023
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (22) , 4564-4574
Top Cited PapersOpen AccessSafety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
Purpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators. Patients and Methods: A total of 153 patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and 161 patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) EC were enrolled and dosed. Patients received 500 mg dostarlimab every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression. Primary endpoints were objective response rate (ORR) and duration of response (DOR). Results: A total of 143 patients with dMMR/MSI-H EC and 156 patients with MMRp/MSS EC were evaluated for efficacy. ORR was 45.5% (n = 65) and 15.4% (n = 24) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. Median DOR for dMMR/MSI-H EC was not met (median follow-up, 27.6 months); median DOR for MMRp/MSS EC was 19.4 months. The ORRs by combined positive score (CPS) ≥1 status were 54.9% and 21.7% for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORRs by high tumor mutational burden (≥10 mutations/Mb) were 47.8% (43/90) and 45.5% (5/11) for dMMR/MSI-H EC and MMRp/MSS EC, respectively. ORR in TP53mut or POLεmut molecular subgroups was 18.1% (17/94) and 40.0% (2/5), respectively. The safety profile of dostarlimab was consistent with previous reports. Conclusions: Dostarlimab demonstrated durable antitumor activity and safety in patients with dMMR/MSI-H EC. Biomarkers associated with EC may identify patients likely to respond to dostarlimab. See related commentary by Jangra and Dhani, p. 4521
- Open Access
- 3 October 2022
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 6 (Suppl) , 23
P051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers
- 3 October 2022
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 6 (Suppl) , 23
Open AccessP051: Serum procalcitonin levels in newly diagnosed classical Hodgkin Lymphoma (cHL): Correlation with other inflammatory biomarkers